RICT 2017
Conferences > Archives > RICT 2017

Confirmed Speakers


Plenary Speakers

 Jean-Philippe ANNEREAU
Jean-Philippe ANNEREAU
ALEXION, Paris, France
Read more

PL12 - Partnering Early to Better Serve Patients Suffering from Rare and Devastating Diseases

 Bernard BARLAAM
Bernard BARLAAM
ASTRAZENECA, Macclesfield, United Kingdom
Read more

PL19 - Identifying High Quality, Potent and Selective Inhibitors of ATM Kinase for Oncology Therapies: Discovery of AZD0156

 Annette BECK-SICKINGER
Annette BECK-SICKINGER
LEIPZIG UNIVERSITY, Leipzig, Germany
Read more

PL02 - Peptide Drugs to Target GPCR- State of the Art and Innovative Application

 Stefano CROSIGNANI
Stefano CROSIGNANI
ITEOS THERAPEUTICS SA, Gosselies, Belgium
Read more

PL06 - Discovery of PF-06840003, a Novel IDO Inhibitor for Cancer Immunotherapy

 Ben DAVIS
Ben DAVIS
OXFORD UNIVERSITY, Oxford, United Kingdom
Read more

PL01 - Sugars & Proteins: Glycomimetics to Target Infectious Disease

 Benoit DEPREZ
Benoit DEPREZ
UNIVERSITY OF LILLE 2, Lille, France
Read more

PL22 - Creating, Varying and Selecting : The Driving Forces in Drug Discovery and Chemical Biology Pierre Fabre Award lecture

 Alexander DÖMLING
Alexander DÖMLING
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
Read more

PL08 - Expanding Screening Decks by Innovative MCR Scaffolds

 Piet HERDEWIJN
Piet HERDEWIJN
KU LEUVEN, Leuven, Belgium
Read more

PL14 - Xeno Nucleic Acids (XNA) in vivo : A New Medicinal Chemistry Approach?

 Tad HOLAK
Tad HOLAK
MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany
Read more

PL15 - Monitoring the Antagonist-Protein and Protein-Protein Interactions with NMR and X-ray: Inhibitors of the p53-Mdm2 and Immune Checkpoint PD-1/PD-L1 Interactions

 Ignace LASTERS
Ignace LASTERS
COMPLIX, Zwijnaarde, Belgium
Read more

PL17 - Engineering Alphabodies to Generate Potent Druggable Inhibitors of Intracellular Protein-Protein Interactions

 Stefan LAUFER
Stefan LAUFER
UNIVERSITY TÜBINGEN, Tübingen, Germany
Read more

PL20 - Raising the Gold Standard: Design & Development of Highly Selective JAK3 Probes (Janus Kinase 3)

 Nicolas MEYER
Nicolas MEYER
ONCOPOLE TOULOUSE, Toulouse, France
Read more

PL04 - Immunotherapy of Cancers: The Lessons of Oncodermatology; Melanoma as a Model

 Ronan O'HAGAN
Ronan O'HAGAN
MERCK, SHARP & DOHME, Boston, United States
Read more

PL03 - Small Molecule Approaches in Immune Modulation in Cancer.

 Didier ROGNAN
Didier ROGNAN
UNIVERSITY OF STRASBOURG, Illkirch, France
Read more

PL09 - First-in-class Extracellular Modulators of Receptor Tyrosine Kinases: from Theory to Practice

 Tanja SCHIRMEISTER
Tanja SCHIRMEISTER
UNIVERSITY OF MAINZ, Mainz, Germany
Read more

PL13 - Allosteric Inhibitors of Dengue and Zika Virus NS3/NS2B Proteases

 Gisbert SCHNEIDER
Gisbert SCHNEIDER
ETH ZÜRICH, Zürich, Switzerland
Read more

PL07 - De Novo Drug Design — Inspiration from Nature

 Hong SHEN
Hong SHEN
F. HOFFMANN-LA ROCHE, Shanghai, China
Read more

PL11 - Structure-based Drug Design (SBDD) in Medicinal Chemistry-enabled Drug Discovery

 Nicolas SOLDERMANN
Nicolas SOLDERMANN
NOVARTIS, Basel, Switzerland
Read more

PL21 - Leniolisib (CDZ173) - Discovery of a New Generation of Potent and Selective PI3Kδ Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases

 Roderich D. SÜSSMUTH
Roderich D. SÜSSMUTH
TECHNICAL UNIVERSITY BERLIN, Berlin, Germany
Read more

PL16 - Bioactive Ribosomal and Non-Ribosomal Peptides from Nature - Structures, Biosynthesis and Engineering Options

 Frédéric TARAN
Frédéric TARAN
CEA/SACLAY, Gif-sur-Yvette, France
Read more

PL10 - Chemoselective and Biocompatible Reactions, New Tools for Heterocyclic Chemistry and Chemical Biology

 Heather TYE
Heather TYE
EVOTEC LTD, Abingdon, United Kingdom
Read more

PL18 - Development of Dual IGF1R/INSR Inhibitors - A Case Study

 Xiaodong WANG
Xiaodong WANG
UNIVERSITY OF NORTH CAROLINA, Chapel Hill, United States
Read more

PL05 - Novel Small Molecule MerTK Inhibitors and their Biological Uses

Keynote Speakers

 Eric DORIS
Eric DORIS
CEA, Gif-sur-Yvette, France
Read more

KL07 - Nanometric Micelles for in vivo Imaging and Drug Delivery

 Mélanie ETHEVE-QUELQUEJEU
Mélanie ETHEVE-QUELQUEJEU
UNIVERSITÉ PARIS DESCARTES, Paris, France
Read more

KL03 - Post-functionalization of RNAs for Specific Conjugations with Peptides and Proteins

 Christelle HUREAU
Christelle HUREAU
LCC CNRS, Toulouse, France
Read more

KL05 - Copper and Zinc as Therapeutic Players in Alzheimer's Disease: With a little Help from Coordination Chemistry.

 Aurelie MALLINGER
Aurelie MALLINGER
INSTITUTE OF CANCER RESEARCH, London, United Kingdom
Read more

KL04 - Discovery of CDK8/CDK19 Kinase Modulators and Evaluation of their Therapeutic Potential

 Kassoum NACRO
Kassoum NACRO
EXPERIMENTAL THERAPEUTICS CENTER, Singapore, Singapore
Read more

KL02 - Mnk1/2 Kinase Inhibitors for the Treatment of Leukemia

 Gilles OUVRY
Gilles OUVRY
GALDERMA R&D, Sophia Antipolis, France
Read more

KL06 - Discovery of Novel TACE Inhibitors for Topical Treatment of Psoriasis

 Vincent RODESCHINI
Vincent RODESCHINI
EDELRIS, Lyon, France
Read more

KL08 - Mining from NP-Like Fragments in 3D: Discovery of a Potent Caspase-1 Inhibitor

 Eric VALEUR
Eric VALEUR
ASTRAZENECA R&D GOTHENBURG, Mölndal, Sweden
Read more

KL01 - New Modalities inspired by nature: from Genetic Encoding of Cyclic Peptides to Hybrid Macrocycles


Organised by

EFMC Sponsored Event

ESOF Labelised Event

Gold Sponsor

Silver Sponsor

Bronze Sponsor

Media Partner

Copyright 2017 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys